{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:09:08Z","timestamp":1784056148043,"version":"3.55.0"},"reference-count":75,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T00:00:00Z","timestamp":1368057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:p>Everolimus is a potent, oral inhibitor of the mammalian target of rapamycin (mTOR) that has been investigated in multiple clinical development programs since 1996. A unique collaboration between academic and pharmaceutical experts fostered research that progressed rapidly, with simultaneous indication findings across numerous tumor types. Initially developed for the prophylaxis of organ transplant rejection, everolimus has demonstrated efficacy and safety for the treatment of patients with various types of cancer (renal cell carcinoma, neuroendocrine tumors of pancreatic origin, and breast cancer) and for adult and pediatric patients with tuberous sclerosis complex. The FDA approval of everolimus for these diseases has addressed several unmet medical needs and is widely accepted by the medical community where treatment options may be limited. An extensive clinical development program is ongoing to establish the role of everolimus as monotherapy, or in combination with other agents, in the treatment of a broad spectrum of malignancies.<\/jats:p>","DOI":"10.1111\/nyas.12122","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T20:33:09Z","timestamp":1368131589000},"page":"14-32","source":"Crossref","is-referenced-by-count":82,"title":["Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases"],"prefix":"10.1111","volume":"1291","author":[{"given":"David","family":"Lebwohl","sequence":"first","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  Florham Park New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"Anak","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Sahmoud","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Klimovsky","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  Florham Park New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Elmroth","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Haas","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Posluszny","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Saletan","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Berg","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,5,9]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"Afinitor (everolimus tablets for oral administration).Afinitor Disperz (everolimus tablets for oral suspension).East Hanover NJ:Novartis Pharmaceuticals Corporation.2012."},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.2.815"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-45"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2011.558079"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.0766"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2010.499121"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.93"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61279-9"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.2012.01084.x"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra055323"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.28.727"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.2.218"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00460.x"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1593\/tlo.09277"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.01.016"},{"key":"e_1_2_12_17_1","unstructured":"Certican. Basel Switzerland: Novartis Pharma AG.2012."},{"key":"e_1_2_12_18_1","unstructured":"Zortress (tablets for oral administration). Stein Switzerland: Novartis Pharma Stein AG.2010."},{"key":"e_1_2_12_19_1","first-page":"393","article-title":"Everolimus\u2010eluting stents in interventional cardiology","volume":"8","author":"Townsend J.C.","year":"2012","journal-title":"Vasc. Health Risk Manage."},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910496"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62127-9"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.02.022"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.02.023"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.07.031"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2012.08.007"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(81)80006-0"},{"key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1016\/S0021-9258(18)91112-9","article-title":"An activated S6 kinase in extracts from serum\u2010 and epidermal growth factor\u2010stimulated Swiss 3T3 cells","volume":"259","author":"Novak\u2010Hofer I.","year":"1984","journal-title":"J. Biol. Chem."},{"key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1073\/pnas.85.2.406","article-title":"Identification and characterization of a mitogen\u2010activated S6 kinase","volume":"85","author":"Jeno P.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.19.7365"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1127"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.5482"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24280"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61039-9"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25219"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.11.027"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.12.057"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.89"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2011.592233"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0955-08.2008"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-8-38"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001671"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073812449904"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182815428"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61134-9"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61767-X"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.7858"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.2669"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61742-X"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.8391"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.8549"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1260-x"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-0928-6"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2837"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6349(06)70583-3"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2402"},{"key":"e_1_2_12_57_1","first-page":"A5619","article-title":"The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor letrozole in breast carninomas [abstract]","volume":"45","author":"Rudloff J.","year":"2004","journal-title":"Proc. Am. Assn. Cancer Res."},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.12.019"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm170"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.0708"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109653"},{"key":"e_1_2_12_62_1","unstructured":"Piccart M.et al.2012.Final progression\u2010free survival analysis of BOLERO\u20102: a phase III trial of everolimus for postmenopausal women with advanced breast cancer. Presented at CTRC\u2010AACR San Antonio Breast Cancer Symposium; December 4\u20138 2012;San Antonio TX."},{"key":"e_1_2_12_63_1","volume-title":"Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER\u20102\u2010overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: a multicenter phase II clinical trial","author":"Dalenc F.","year":"2010"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2321"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.02.014"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27505"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200911-1720OC"},{"key":"e_1_2_12_68_1","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology\u2122 Kidney Cancer (version 1.2013).2013.http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf. Accessed March 11 2013."},{"key":"e_1_2_12_69_1","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology\u00ae Breast Cancer (Version 3.2012).2012.http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed March 11 2013."},{"key":"e_1_2_12_70_1","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology\u2122 Neuroendocrine Tumors (Version 1.2012).2012.http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf. Accessed March 11 2013."},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq206"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds227"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq160"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds295"},{"key":"e_1_2_12_75_1","volume-title":"TSC Clinical Consensus Conference: Summary of Updated Diagnosis, Treatment and Surveillance Guidelines","author":"Krueger D.","year":"2012"},{"key":"e_1_2_12_76_1","unstructured":"Tuberous Sclerosis Association.2011.Clinical guidelines for the care of patients with TSC: a summary.http:\/\/www.tuberous\u2010sclerosis.org\/publications\/clinical_ guidelines_for_the_care_of_patients_with_TSC.pdfAccessed March 11 2013."}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnyas.12122","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nyas.12122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T10:52:37Z","timestamp":1695639157000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/nyas.12122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,9]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1111\/nyas.12122"],"URL":"https:\/\/doi.org\/10.1111\/nyas.12122","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,9]]}}}